Finding it difficult to quell the bad press despite a press conference earlier this week, Ranbaxy CEO, Malvinder Mohan Singh on Friday decided to break his silence. In an exclusive chat with NDTV Profit, Malvinder Singh said that Daiichi Sankyo was not aware of some of the allegations made by the USFDA at the time of signing the deal.